Published in final edited form as:

Eur J Cancer. 2012 May ; 48(7): 1116–1117. doi:10.1016/j.ejca.2012.02.061.

Burden of extragonadal germ cell tumours in Europe and the United States

A. Stang^{*}, B. Trabert[†], N. Wentzensen[†], M. B. Cook[†], C. Rusner^{*}, J. W. Oosterhuis[‡], and K. A. McGlynn[†]

^{*}Institut für Klinische Epidemiologie, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany [†]Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20852-7234, USA [‡]Josephine Nefkens Institute, Department of Pathology, Erasmus MC, Rotterdam, Netherlands

Dear Sirs,

We read with interest the recent publication by Trama et al. about the burden of testicular, paratesticular and extragonadal germ cell tumours in Europe in this journal(1). We did comparable analyses based on data from the Surveillance, Epidemiology and End Results (SEER) Program, original nine registries for the years 1973-2007(2). Many statistical figures on extragonadal germ cell tumours (EGCTs) are similar in the U.S. and Europe. For example, we also observed that mediastinal EGCTs had the worst 5-year relative survival (SEER: 58%, Europe: 53%). However, the estimated age-standardized incidence rate of EGCTs is considerably higher in the U.S. than Europe. To quantify this difference, we calculated the ratio of age-standardized incidence rates (SEER estimate, whites, 1997-2007 / European estimate 1995-2002) and corresponding 95% confidence intervals for males and females(3). Among males, the EGCT rate in the U.S. is 1.82 (95%CI: 1.58-2.10) times higher than in Europe. Among females, the EGCT rate in the U.S. is 2.46(95%CI: 1.94-3.12) times higher than in Europe. As rate estimates were quite precise in both regions, random error is an unlikely explanation for this finding.

In contrast to Trama et al., we included EGCTs of the placenta (all nondysgerminoma). 312 out of 567 EGCTs among white females (55%) during the period 1973-2007 originated from the placenta. When we exclude placental EGCTs, the age-standardized incidence of EGCT among white females for the period 1997-2007 decreases to 1.1 per million person-years (standard error [SE]: 0.10) resulting in a US:Europe ratio of 1.59 (95%CI: 1.25-2.02). We provide some hypotheses that might explain these differences. First, EGCTs are only rarely

© 2012 Elsevier Ltd. All rights reserved.

Address for correspondence: Andreas Stang, Institute of Clinical Epidemiology, Medical Faculty, Martin-Luther-University of Halle-Wittenberg, Magdeburger Str. 8, 06097 Halle (Saale), Phone +49-345-557-3596, Fax +49-345-557-3565, andreas.stang@medizin.uni-halle.de.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

registered and can be easily miscoded as gonadal germ cell tumours if the topography coding of tumours is not intensively monitored. In contrast to the SEER program, the European analysis was based on 64 cancer registries located throughout Europe with varying degrees of quality control and varying degrees of completeness of registration(4).Second, EGCT cancer registry reports that contain only unspecified histology (e.g. carcinoma, not otherwise specified) cannot be included in the data analysis of EGCTs. A comparison of the number of extragonadal tumours with unspecified histologies at typical sites of EGCTs (e.g. mediastinum, pineal gland, retroperitoneum, brain) might give clues to this hypothesis. Finally, different prevalences of the, until now, unknown risk factors of EGCTs in the U.S. and Europe may play a role.

Interestingly, in a recent unpublished pooling project of 9 population-based cancer registries in Germany of the years 1998-2008 which included 362,450,458 person-years, we estimated an age-standardized (European standard population) incidence rate for male EGCTs, female EGCTs including placental EGCTs, and female EGCTs excluding placental EGCTs of 1.79 (SE 0.1), 1.14 (SE 0.09), 0.79 (SE 0.08), respectively, which is very much in line with European-wide estimates.

Acknowledgments

Funding: Funding for this research was provided through a grant from the Deutsche Forschungsgemeinschaft (DFG), (grant number RU 1659/1-1).

Reference List

1. Trama A, Mallone S, Nicolai N, et al. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. *Eur J Cancer*. Jan. 2012; 48(2):159–169. [PubMed: 22142457]
2. Stang A, Trabert BL, Wentzensen N, et al. Gonadal and extragonadal germ cell tumours in the United States, 1973-2007. *Int J Androl*. 2012 doi:10.1111/j.1365-2605.2011.01245.x.
3. Boyle, P.; Parkin, DM. Statistical methods for registries.. In: Jensen, OM.; Parkin, DM.; MacLennan, R., editors. *Cancer registration: principles and methods*. Lyon: 1991. p. 136-137.
4. Gatta, G.; van der Zwan, JM.; Siesling, S.; Otter, R.; Tavilla, A.; Mallone, S. [2012 Jan 31] Technical report with basic indicators for rare cancers and health care related macro indicators.. *Surveillance of rare cancers in Europe*. 2010. Available from: URL: <http://www.rarecare.eu>

Table

Comparison of Incidence Rates of Extragonadal Germ Cell Tumours in the U.S. and Europe

	SEER 1997-2007 (Whites)	Europe 1995-2002	US:Europe Rate Ratio (95% confidence interval)
Male cases (N)	384	n.r.	
Incidence rate per million/year (standard error)	3.4 (0.17)	1.87 (0.07)	1.82 (1.58-2.10)
Female Cases (N)	185	n.r.	
Incidence rate per million/year (standard error)	1.7 (0.13)	0.69 (0.04)	2.46 (1.94-3.12)

Legend: n.r.: not reported; according to Trama et al., the overall number (males and females) of extragonadal germ cell tumors was 1,019; all rates are standardized to the European standard population.